Related references
Note: Only part of the references are listed.Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjorn Berentsen et al.
BLOOD (2017)
Anticomplement 05 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Edwin K. S. Wong et al.
TRANSLATIONAL RESEARCH (2015)
Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity
Roman Shapiro et al.
CLINICAL CASE REPORTS (2015)
Long-term response of refractory primary cold agglutinin disease to eculizumab therapy
Neha Gupta et al.
ANNALS OF HEMATOLOGY (2014)
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia
Sigbjorn Berentsen et al.
BLOOD REVIEWS (2012)
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
Alexander Roeth et al.
BLOOD (2009)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
P Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
